Phase 1Data readout

NBIP-2118 (CRF2 Peptide Agonist)

Obesity

NBIXNeurocrine Biosciences

Expected catalystDecember 31, 2027Company guidance: Dec 31, 2027

Catalyst overview

Event details

Drug or asset: NBIP-2118 (CRF2 Peptide Agonist)
Development stage: Phase 1
Event type: Data readout
Indication: Obesity

Research summary

What is being tracked?

This catalyst tracks a Phase 1 data readout for NBIP-2118 (CRF2 Peptide Agonist) in Obesity. The expected timing is based on the latest available company guidance and may change.

Development notes

05/04/26:- Phase 1 initiated; initial safety data expected in 2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source